logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Sarepta Therapeutics, Inc.


USPTO Granted Patents = 122



Trademarks = 56

Forward Citations = 1,691

Loading Chart...
Loading Chart...

90 inventors (with patents filed for the assignee):

goldMedal Gunnar J Hanson (39 out of 181 patents)

silverMedal Patrick L Iversen (36 out of 95 patents)

bronzeMedal Dwight D Weller (27 out of 61 patents)

4.  Ryszard M Kole (23 out of 29 patents)

5.  Richard Keith Bestwick (17 out of 18 patents)

6.  Ming Zhou (12 out of 32 patents)

7.  Frederick Joseph Schnell (10 out of 10 patents)

8.  Marco A Passini (10 out of 25 patents)

9.  David A Stein (9 out of 24 patents)

10.  Baozhong Cai (8 out of 8 patents)

11.  Bao Zhong Cai (8 out of 9 patents)

12.  Dan V Mourich (8 out of 11 patents)

13.  Mitchell Martini (7 out of 7 patents)

14.  Ross Shimabuku (7 out of 7 patents)

15.  Katie Thomas (7 out of 7 patents)


Core Competencies:
Adeno-Associated Virus
Oligonucleotide Analogues
Exon Skipping
Antisense Oligomers
Peptide Oligonucleotide Conjugates
Muscular Dystrophy
Chimeric Peptides
Phosphorodiamidate Morpholino Oligomers
Cell-Penetrating Peptides
Rett Syndrome
Myotonic Dystrophy
Expanded Repeat Diseases

122 patents:

1. 12391745 - Adeno-associated virus antibodies and fragments thereof (2025-08-19),
2. 12377150 - Exon skipping oligomer conjugates for muscular dystrophy (2025-08-05),
3. 12370261 - Chimeric peptides for antisense delivery (2025-07-29),
4. 12297219 - Phosphorodiamidate morpholino oligomers (2025-05-13),
5. 12286630 - Treatment methods for muscular dystrophy (2025-04-29),
6. 12258362 - Processes for preparing phosphorodiamidate morpholino oligomers (2025-03-25),
7. 12239715 - Peptide oligonucleotide conjugates (2025-03-04),
8. 12168059 - Trimeric peptides for antisense delivery (2024-12-17),
9. 12139709 - Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene (2024-11-12),
10. 12138312 - Cell-penetrating peptides for antisense delivery (2024-11-12),
11. 12121532 - Modified antisense oligomers for exon inclusion in spinal muscular atrophy (2024-10-22),
12. 12104163 - Adeno-associated virus vectors for treatment of Rett syndrome (2024-10-01),
13. 11932851 - Exon skipping compositions for treating muscular dystrophy (2024-03-19),
14. 11925675 - Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy (2024-03-12),
15. 11911403 - Antisense-induced exon exclusion in type VII collagen (2024-02-27),
Sarepta Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of precision genetic medicines for rare neuromuscular diseases. With a strong commitment to advancing scientific research and improving patient lives, Sarepta is driven to deliver innovative therapies that address the underlying causes of these debilitating conditions. Through its dedication to precision medicine, Sarepta aims to transform the lives of patients suffering from rare genetic diseases.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
122 Patents

#22 in Cambridge, MA

#173 in Massachusetts

#3,043 in US

#6,351 in the World

...
Cambridge, MA, United States of America

Sarepta Therapeutics, Inc.

Forward Citations = 1,691

90 inventors:

goldMedal Gunnar J Hanson (39 out of 181 patents)

silverMedal Patrick L Iversen (36 out of 95 patents)

bronzeMedal Dwight D Weller (27 out of 61 patents)

4.  Ryszard M Kole (23 out of 29 patents)

5.  Richard Keith Bestwick (17 out of 18 patents)

Please report any incorrect information to support@idiyas.com
Loading…